Switzerland, Inter-Country Surrogacy and Public Policy
By Michael Wells-Greco,
BioNews
| 06. 08. 2015
Untitled Document
On 21 May 2015 the Swiss Federal Court (1) refused to register a male couple - who are in a civil partnership and living in Saint-Gallen, Switzerland - as the legal fathers of a child born following an inter-country surrogacy arrangement.
The background to this case is that the child was born in California to a gestational surrogate, with one of the intending fathers providing the sperm, which was used to fertilise an egg from an anonymous donor. With the consent of the surrogate, and following a judgment of a Californian court, the intending fathers were named as the legal parents and their names were recorded in the child's US birth certificate. The family returned to Switzerland and took steps to be recognised as the child's legal parents.
Read more...
SOURCES & REFERENCES
(1) 5A_748/2014
Image via Wikimedia Commons
Related Articles
By Judd Boaz and Elise Kinsella, ABC News | 03.17.2026
By Gabriele Pichlhofer and Tino Plümecke, Guest Contributors
| 03.25.2026
A German translation of this interview will be published in May 2026 in the German GID MAGAZIN, which focuses on the market for reproductive technologies. For more information, visit: Gen-ethisches Netzwerk
Egg donation is currently prohibited in Germany and Switzerland, but both countries have been debating its legalization for years. In Switzerland, a legal framework is currently being developed, with a first draft expected by the end of the year. Yet the debate rarely draws on scientific evidence. Instead...
By Charles Pulliam-Moore, The Verge | 03.21.2026
Like many people, director Valerie Veatch was intrigued when OpenAI first released its Sora text-to-video generative AI model to the public in 2024. Though she didn’t fully understand the technology, she was curious about what it could do, and she...
By Ritsuko Kawai, Wired | 03.14.2026
On March 6, Japan’s Ministry of Health, Labor and Welfare officially granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed iPS cells, marking exactly 20 years since the creation of mouse iPS cells.These will...